Upper gastrointestinal - oncology - SA Health Approved Cancer Chemotherapy Protocol Register

Gastric and oesophageal

Gastric and oesophageal
Protocol Administration at chemotherapy unit level Review Date
Gastric adjuvant CAPOX (XELOX) (capecitabine and oxaliplatin) Medium February 2023
Gastric and gastroesophageal metastatic cISplatin capecitabine trastuzumab Medium. Moves to low risk after completion of cISplatin/capecitabine treatment February 2023
Gastric and gastroesophageal metastatic CAPOX (XELOX) (capecitabine and oxaliplatin)
Medium February 2022
Gastric and gastroesophageal metastatic cISplatin fluorouracil trastuzumab Medium2(Moves to low risk after completion of cISplatin/fluorouracil treatment) February 2023
Metastatic trifluridine/tipiracil Low August 2021
*Gastric and gastroesophageal metastatic DOCEtaxel Medium February 2023
*Gastric and gastroesophageal metastatic FOLFIRI (modified) (fluorouracil leucovorin irinotecan) Medium2 February 2023
*Gastric and gastroesophageal metastatic FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin) Medium February 2023
Gastric and gastroesophageal metastatic FOLFOX6 (modified) and trastuzumab
Medium2 February 2022
*Gastric and gastroesophageal metastatic CAPOX (XELOX) (capecitabine and oxaliplatin) and trastuzumab
Medium2 February 2022
*Gastric and gastroesophageal metastatic irinotecan (two weekly) Medium February 2023
*Gastric and gastroesophageal metastatic PACLitaxel (weekly) Medium February 2023
*Gastric and gastroesophageal neoadjuvant and adjuvant FLOT (fluorouracil leucovorin oxaliplatin and DOCEtaxel) Medium2 February 2023
Gastric and oesophageal metastatic cISplatin capecitabine Medium February 2023
Gastric and oesophageal metastatic cISplatin fluorouracil Medium2 February 2023
Gastroesophageal and oesophageal advanced or metastatic CAPOX and nivolumab – Interim (for information on this protocol please contact the *_ SA Health Cancer Drug Committee_).*
Medium February 2022
Gastroesophageal and oesophageal advanced or metastatic FOLFOX6 (modified) and nivolumab – Interim (for information on this protocol please contact the *_ SA Health Cancer Drug Committee_).*
Medium February 2022
Oesophageal definitive cISplatin and fluorouracil chemoradiation followed by cISplatin and fluorouracil Medium2 August 2024
Oesophageal definitive FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin) chemoradiation Medium2 February 2023
Oesophageal neoadjuvant cARBOplatin and PACLItaxel weekly chemoradiation pre-operative Medium February 2023
Oesophageal neoadjuvant cISplatin and fluorouracil chemoradiation Medium2 February 2023

Gastrointestinal stromal cell tumours

Gastrointestinal stromal cell tumours
Protocol Administration at chemotherapy unit level Review Date
Gastrointestinal stromal cell tumour (GIST) adjuvant imatinib Low February 2023
Gastrointestinal stromal cell tumour (GIST) metastatic imatinib Low February 2023
Gastrointestinal stromal cell tumour (GIST) metastatic regorafenib Low3 February 2023
Gastrointestinal stromal cell tumour (GIST) metastatic sunitinib Low February 2023

Hepatic

Hepatic
Protocol Administration at chemotherapy unit level Review Date
Advanced or Metastatic nivolumab (flat dosing) Low August 2021
Advanced or Metastatic nivolumab (weight based dosing) Low August 2021
Hepatic advanced or metastatic atezolizumab and bevacizumab
Low February 2022
Hepatic advanced or metastatic lenvatinib Low February 2023
Hepatic advanced sorafenib Low February 2023

Neuroendocrine

Neuroendocrine
Protocol Administration at chemotherapy unit level Review Date
Neuroendocrine advanced capecitabine and temozolomide Medium February 2023
Neuroendocrine advanced cARBOplatin etoposide Medium February 2023
Neuroendocrine advanced cISplatin and etoposide Medium February 2023
Neuroendocrine advanced lanreotide (somatuline autogel) Low February 2023
Neuroendocrine advanced octreotide (sandostatin LAR) Low February 2023
Neuroendocrine advanced telotristat ethyl Low3 February 2023
Neuroendocrine pancreatic advanced everolimus Low February 2023
Neuroendocrine pancreatic advanced sunitinib Low February 2023

Pancreas and biliary

Pancreas and biliary
Protocol Administration at chemotherapy unit level Review Date
Biliary and gallbladder advanced cARBOplatin and gemcitabine Medium Day 1. Low day 8 February 2023
Biliary and gallbladder advanced cISplatin and gemcitabine Medium February 2023
Biliary and gallbladder advanced FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin) INTERIM
Medium2 February 2022
Biliary and gallbladder advanced gemcitabine Low February 2023
Biliary tract cancer adjuvant capecitabine Low February 2022
Pancreas adjuvant capecitabine and gemcitabine Medium August 2024
Pancreas adjuvant FOLFIRINOX (modified) (fluorouracil leucovorin irinotecan oxaliplatin) Medium2 February 2023
Pancreas adjuvant gemcitabine Low February 2023
Pancreas advanced gemcitabine Low February 2023
Pancreas capecitabine chemoradiation Low February 2023
Pancreas fluorouracil chemoradiation Low February 2023
Pancreas metastatic FOLFIRI (modified) (fluorouracil leucovorin irinotecan) Medium2 August 2024
Pancreas metastatic FOLFIRINOX (modified) (fluorouracil leucovorin irinotecan oxaliplatin) Medium2 February 2023
Pancreas metastatic gemcitabine and nab-PACLItaxel Medium February 2023
Pancreas metastatic irinotecan nanoliposomal, fluorouracil and leucovorin Medium2 August 2024
Pancreas metastatic OFF (oxaliplatin fluorouracil leucovorin) Medium February 2023

Notes

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Non-formulary drug included in the protocol
  4. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.